Autolus Therapeutics PLC (AUTL)
2.94
+0.10
(+3.52%)
USD |
NASDAQ |
Nov 22, 16:00
2.945
0.00 (0.00%)
After-Hours: 20:00
Autolus Therapeutics Cash from Financing (Quarterly): 0.185M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.185M |
| June 30, 2024 | -2.079M |
| March 31, 2024 | 561.44M |
| December 31, 2023 | 0.023M |
| September 30, 2023 | 0.004M |
| June 30, 2023 | -0.219M |
| March 31, 2023 | -0.691M |
| December 31, 2022 | 223.51M |
| September 30, 2022 | 0.102M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | -0.001M |
| December 31, 2021 | 147.42M |
| Date | Value |
|---|---|
| September 30, 2021 | -0.23M |
| June 30, 2021 | 13.55M |
| March 31, 2021 | 123.32M |
| December 31, 2020 | 0.392M |
| September 30, 2020 | 0.01M |
| June 30, 2020 | -0.297M |
| March 31, 2020 | 74.31M |
| December 31, 2019 | 0.034M |
| September 30, 2019 | -0.576M |
| June 30, 2019 | 109.40M |
| March 31, 2019 | 0.004M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.079M
Minimum
Jun 2024
561.44M
Maximum
Mar 2024
57.04M
Average
0.0285M
Median
Cash from Financing (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 25.00M |
| TC BioPharm (Holdings) PLC | 1.183M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | -0.0888M |
| Bicycle Therapeutics PLC | -31.93M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -76.74M |
| Cash from Investing (Quarterly) | -9.589M |
| Free Cash Flow | -205.61M |
| Free Cash Flow Per Share (Quarterly) | -0.3244 |
| Free Cash Flow Yield | -30.13% |